Fibrin

TargED Biopharmaceuticals has initiated clinical development of TGD001, a thrombolytic designed to dissolve clots of all sizes and compositions. The first participant was dosed on 18 December in a Phase 1 study in Germany, evaluating safety, tolerability, and pharmacokinetics. First safety read-out expected by mid-2025, with further trials planned in acute ischaemic stroke and iTTP patients. TGD001 is a first-in-class fusion protein drug targeting clots via a unique two-step mode of action, aiming to reduce bleeding risk.

FDA approves Grifols' VISTASEAL fibrin sealant for surgical bleeding control in pediatric patients, achieving 95% efficacy and rapid hemostasis within 4 minutes, with comparable safety profiles to active control.

Grifols received FDA approval for its Fibrin Sealant (FS) to treat surgical bleeding in pediatric patients in the U.S., marketed as VISTASEAL™ in the U.S./Canada and VERASEAL™ in Europe. The plasma-protein based solution, combining fibrinogen and thrombin, demonstrated >95% efficacy in achieving hemostasis within four minutes in a phase 3b study involving 178 patients across 18 centers. Distributed through a strategic collaboration with Johnson & Johnson MedTech, the product is available in 18 countries.

Neurological diseases like Alzheimer's and MS are linked by blood leaking into the brain, triggering a toxic immune reaction. Katerina Akassoglou's research identifies fibrin as a key protein causing this cascade, and neutralizing it could protect against multiple diseases. A fibrin-targeting immunotherapy is in Phase 1 trials, suggesting a new era of interdisciplinary research for neurological disease treatment.

Fibrin hydrogels were prepared using fibrin glue, forming 0.6 mm thick scaffolds. LESCs were isolated from pig eyes, cultured, and seeded on fibrin scaffolds. Scaffold preparation parameters were optimized for cell seeding. Cells were cultured on traditional and bioprinted scaffolds, with stability and viability analyzed post-bioprinting. Cell distribution, line characteristics, and culture spread on fibrin were studied. Immunofluorescent staining confirmed stem cell markers, and statistical analysis was conducted.

Tenecteplase (TNK) is a thrombolytic drug that may break down blood clots after a stroke, though not yet FDA-approved. It is administered as a single intravenous dose, targeting blood clots more effectively than alteplase, with a longer active duration and potentially lower cost. Risks include bleeding and thromboembolism. Ongoing trials aim to confirm its efficacy and safety for stroke treatment.